TacticScaleWhat Incyte Does & How It Makes Money (INCY)
Updated October 2026 · reflects Incyte's latest reported financials
Biopharma company developing and selling drugs for blood cancers and skin diseases. Incyte earns revenue mainly by selling its approved drugs through specialty and retail pharmacies, hospital pharmacies and distributors in the US, Europe, Canada and Japan.
How Incyte makes money
Incyte earns revenue mainly by selling its approved drugs through specialty and retail pharmacies, hospital pharmacies and distributors in the US, Europe, Canada and Japan. It also has collaboration and license agreements with partners including Novartis, Lilly and Syndax.
What Incyte does
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company, founded in 1991 as Incyte Genomics and renamed in 2003. Its commercial portfolio is centered on hematology and oncology. The lead product is JAKAFI, used for myelofibrosis, polycythemia vera and steroid-refractory acute graft-versus-host disease. Other marketed products include ICLUSIG for chronic myeloid leukemia, MONJUVI/MINJUVI for diffuse large B-cell and follicular lymphoma, NIKTIMVO for chronic graft-versus-host disease, PEMAZYRE for bile duct cancers, and ZYNYZ for Merkel cell carcinoma. Incyte's pipeline goes beyond cancer into inflammation and dermatology. Candidates include ruxolitinib cream and povorcitinib for hidradenitis suppurativa, vitiligo, prurigo nodularis and other conditions, along with several programs for myeloproliferative neoplasms, ovarian cancer, solid tumors and the rare bone disease fibrodysplasia ossificans progressiva. The company sells through pharmacy and distributor channels and has partnerships with Novartis, Lilly and Syndax.
Products & services
- JAKAFI (ruxolitinib)
- ICLUSIG
- MONJUVI/MINJUVI
- NIKTIMVO
- PEMAZYRE
- ZYNYZ
What is Incyte worth?
On an owner-earnings DCF, Incyte's most-likely value is about $204 versus a recent price near $113 (81% below fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$102) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →